Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria

Inclusion Criteria: * A male aged 18-55 years at the time of screening. * Assigned to the battalion of study and programmed to accompany it to eastern Indonesia for the duration of the deployment. * Freely provides written informed consent to participate in the study. * Agrees to adhere to Indonesian military medical guidance regarding screening and treatment of malaria. * Physical examination and laboratory results without clinically significant findings that would jeopardize the safety of the participant or the integrity of the study, and a body mass index (BMI) ≤35 kg/m\^2. Exclusion Criteria: * Previous vaccination with an investigational malaria vaccine. * Use of an investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days before the first study vaccination, or planned use up to 30 days after last vaccination. * Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs within six months before the first vaccination. This includes any dose level of oral steroids, but not inhaled steroids or topical steroids. * Administration or planned administration of 1 live or 3 or more other type vaccines in the period beginning 28 days before the first study vaccination and ending 28 days after the last vaccination. * Confirmed or suspected immunosuppressive or immunodeficient condition. * Confirmed or suspected autoimmune disease. * History of allergic reactions or anaphylaxis to CQ or other 4…